Key result
Montanide ISA 201 and 206 adjuvanted FMD vaccines elicited a protective humoral immune response by the 2nd week post-vaccination, with ISA 201 showing the most rapid cellular immune response peaking at 14 days.
Why the study?
Does the choice of Montanide ISA adjuvant (201, 206, 61, or 50) improve the immune response to a trivalent foot and mouth disease vaccine in animals?
Does the choice of Montanide ISA adjuvant (201, 206, 61, or 50) improve the immune response to a trivalent foot and mouth disease vaccine in animals?
p-value: p=<0.05
Montanide ISA 201 is superior to ISA 206, 61, and 50 in eliciting a rapid cellular and humoral immune response when used as an adjuvant in trivalent foot and mouth disease vaccines.
No takes yet. Share an insight, caveat, or question.
May guide adjuvant selection for faster FMD immunity onset; hypothesis-generating pending field validation.
Ibrahim et al. (2015) studied Foot and mouth disease (FMD) vaccination (n=25). Montanide ISA 201, 206, 61, and 50 adjuvanted trivalent FMD vaccines vs. Unvaccinated control was evaluated on Humoral and cellular immune response (SNT and ELISA antibody titers, and lymphocyte proliferation) (p=<0.05). Montanide ISA 201 and 206 adjuvanted FMD vaccines elicited a protective humoral immune response by the 2nd week post-vaccination, with ISA 201 showing the most rapid cellular immune response peaking at 14 days.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: